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a Commercial Calcium-containing Dialysate
YL Cheng, AWY Yu, HW Chan, YT Tsui, CK Wong, KY Tsang, KY Chung,
SC Ng, LC Cheung, WK Chan, FSY Wong, CU Yung
Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po,
Hong Kong SAR, China.
Background:  By chelating ionized calcium (iCa), regional citrate
anticoagulation for HD has been proven to reduce bleeding complication in
high risk patients. However, the complexity of the HD circuit and the citrate
associated metabolic complications impeded the popularity of this approach.
In the present study, we attempted to use low dose citrate and to simplify the
circuit by using a conventional calcium-containing dialysate. Methods: Twelve
patients (8 male, 4 female; mean age, 59 ( 14 years) with high risk of bleeding
requiring HD treatment were studied. Each patient was dialysed for 4 hours
using a Polyflux 8L dialyser. Blood flow was kept at 200 mL/min. A dialysate
containing 1.25 mmol/L calcium was used, and the sodium and bicarbonate
content were set at 135 and 32 mmol/L, respectively. Anticoagulant citrate
dextrose–formula A solution was infused into the afferent blood line at a rate
of 340 mL/hr (citrate, 25.4 mmol/hr). Calcium infusion was not required. Acid-
base status, electrolytes, iCa, dialyser urea clearance (UrCl) and creatinine
clearance (CrCl) were monitored. Results: The results (mean ( SD) are shown
in the table below. All the dialysis treatments were uneventful and well tolerated.
Manifestations of citrate toxicity or hypocalcemia were not observed. There
was no significant difference in the 15-minute and 4-hour dialyser UrCl and
CrCl. All the dialysers passed the fiber bundle volume test after reprocessing
and could be reused.
Serum iCa, Prefilter iCa, UrCl, CrCl,
mmol/L mmol/L mL/min  mL/min
Predialysis 1.03 ( 0.10 0.31 ( 0.04* 193 ( 3* 174 ( 7*
Postdialysis 1.05 ( 0.09 0.31 ( 0.05* 192 ( 4* 169 ( 11
p > 0.05 > 0.05 > 0.05 > 0.05
*Taken 15 minutes after start of HD.
Conclusion: Our results suggest that the present citrate protocol is simple, safe,
effective, and will be useful in dialysing patients with a high risk of bleeding.
Risk Factors and Outcomes of ESBL-producing E. coli Peritonitis in
CAPD Patients
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Background: To determine the risk factors and outcomes of CAPD peritonitis
caused by extended spectrum beta-lactamase (ESBL)-producing E. coli.
Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994
to August 2003 were reviewed. The demographic data, underlying medical
conditions, recent use of gastric acid inhibitors (including H2-antagonists and
proton pump inhibitors) and recent antibiotic therapy, antibiotic regimen for
the peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical
outcomes were examined. Results: Over a 10-year study period, 88 episodes
of E. coli peritonitis were recorded; 11 cases were caused by ESBL-producing
E. coli. The recent use of cephalosporins and gastric acid inhibitors is associated
with the development of ESBL-producing E. coli peritonitis. Compared with
non-ESBL-producing E. coli peritonitis, more cases in the ESBL-producing
E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died
of sepsis (27.3% vs 3.9%, p = 0.02). The peritoneal failure rate was also higher
in the ESBL-producing E. coli group, but the difference was not statistically
significant (18.2% vs 3.9%, p = 0.12). Conclusion: Peritonitis caused by ESBL-
producing E. coli is associated with worse clinical outcomes. The use of
cephalosporins and gastric acid inhibitors may contribute to its development.
Further studies are warranted to investigate and determine the predisposing
factors for ESBL-producing E. coli peritonitis.
Transport of Small Solutes in Peritonitis-free PD Patients
MF Lam, WK Lo, C Tang, SL Lui, TM Chan, KN Lai
Division of Nephrology, Department of Medicine, The University of Hong
Kong, Pokfulam, Hong Kong SAR, China.
Background: Adverse risk factors for peritoneal membrane related to uremia,
glucose exposure and peritonitis, which increase with time on PD treatment.
We studied longitudinal changes of small solutes transport in the absence of
peritonitis and investigated the impact of glucose exposure. Methods: Patients
who had started on PD between 1996 and 2002 from two dialysis centers were
screened. Patients who had been on PD for more than 2 years without any
history of peritonitis were recruited. A peritoneal equilibration test (PET) was
performed at 1 month (baseline) and then performed annually; the amount of
glucose dialysate used for each patient was recorded. Results: In total, 87
patients (38 women) were recruited. Mean age was 57.7 ( 15.3 years; 27 (31%)
patients were diabetic. PD duration was 4.63 ( 1.7 years. Baseline and 1st year
D/P Cr were 0.73 ( 0.13 (n = 76) and 0.69 ( 0.10 (n = 76; p = 0.002),
respectively. A decrease in D/P Cr was found in both high (H) and high average
(HA) transport groups. [H group, n = 14; D/P Cr, 0.93 ( 0.07 (baseline) and
0.77 ( 0.10 (1st year); p < 0.0001]. [HA group, n = 22; D/P Cr, 0.78 ( 0.04
(baseline) and 0.69 ( 0.07 (1st year); p < 0.0001]. However, throughout the
dialysis period, patients with elevated D/P Cr did not have significantly higher
glucose exposure than patients with static D/P Cr. Conclusion: We demonstrated
a natural centripetal tendency of peritoneal transport in peritonitis-free patients
at the 1st year evaluation. The amount of glucose exposure to the peritoneal
membrane of patients with increased solutes transport did not differ significantly
from that of patients with static solutes transport.
Increased Serum Leptin Levels During PD-related Peritonitis Associated
with Prolonged Inflammation and Loss of Lean Body Mass
MF Lam, JCK Leung, S Tam, KC Tse, SL Lui, WK Lo, TM Chan, KN Lai
Division of Nephrology, Department of Medicine, The University of Hong
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Background: Elevated serum leptin levels have been shown in patients on
peritoneal dialysis (PD), and this is associated with a loss of lean body mass.
We investigated whether leptin levels are further increased when PD patients
experience peritonitis. Methods: This was a prospective study. Blood samples
were obtained at baseline (D0) before the onset of peritonitis. Once peritonitis
developed, patients were recruited into the study; and blood samples were
collected for leptin, adiponectin and inflammation markers on day 1 (D1), 7
(D7) and 42 (D42). Lean body mass was calculated from urine and dialysate
creatinine clearance. Results: In total, 43 patients (21 women) were recruited.
Mean age was 63.0 ( 13.1 years; 15 (35%) patients were diabetic. The median
duration of PD and residual renal function at the time of peritonitis was 3.4
years (range, 0.1–20.1 years) and 0.0 mL/min/1.73m2 (range, 0.0–6.1 mL/min/
1.73m2). Serum leptin and inflammatory markers were elevated, but adiponectin
was not. Leptin was negatively correlated with adiponectin (r = –474; p <
0.001), but there was no significant correlation with inflammatory markers.
HsCRP levels were positively correlated with IL-6 and TNF_, and negatively
correlated with serum albumin levels. For patients who responded to IP
antibiotics treatment (74.4%), lean body mass decreased significantly from
33.0 ( 10.8 kg to 29.6 ( 8.1 kg (p < 0.000). Conclusion: This prospective
study showed that serum leptin levels increased during peritonitis as did other
inflammatory markers, which may contribute to the loss of lean body mass.
Peritonitis induced prolonged systemic inflammation even after the episode of
peritonitis had been resolved.
